首頁 › 多發性骨髓瘤 › 德克薩斯州

德克薩斯州的多發性骨髓瘤臨床試驗

53 項針對多發性骨髓瘤的研究正在德克薩斯州各地點尋找參與者。

德克薩斯州的城市

官方研究文本（英文）

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

Research Site, Austin
Research Site, Dallas
Research Site, Houston

招募中3 期

18 歲及以上 · 所有性別 · 更新於 2026年9月29日 · NCT07391657

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

MD Anderson Cancer Center, Houston

招募中1 期

18 歲及以上 · 所有性別 · 更新於 2026年9月28日 · NCT05652335

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Baylor University Medical Center, Dallas
Joe Arrington Cancer Research Treatment Center, Lubbock

招募中3 期

18 歲及以上 · 所有性別 · 更新於 2026年9月25日 · NCT07518186

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

Research Site, Houston

招募中1 期

18 歲及以上 · 所有性別 · 更新於 2026年9月25日 · NCT07073547

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

St. David's South Austin Medical Center, Austin
Baylor University Medical Center, Dallas
UT Southwestern Medical Center, Dallas
還有 2 項

招募中3 期

18 歲及以上 · 所有性別 · 更新於 2026年9月25日 · NCT07258511

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

MD Anderson, Houston

招募中1/2 期

18 歲及以上 · 所有性別 · 更新於 2026年9月25日 · NCT07336472

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

University of Texas Southwestern Medical Center, Dallas
Houston Methodist Hospital, Houston
Joe Arrington Cancer Research Treatment Center, Lubbock

招募中3 期

18 歲及以上 · 所有性別 · 更新於 2026年9月25日 · NCT05552222

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

The University of Texas MD Anderson Cancer Center, Houston

招募中3 期

18 歲及以上 · 所有性別 · 更新於 2026年9月25日 · NCT05623020

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

MD Anderson Cancer Center, Houston

招募中4 期

18 歲及以上 · 所有性別 · 更新於 2026年9月25日 · NCT05201781

A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

Oncology Consultants (P1 Trials -Exigent Network), Houston
Lumi Research, Houston

招募中1 期

18 歲及以上 · 所有性別 · 更新於 2026年9月24日 · NCT07477587

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Texas Oncology - The Woodlands /ID# 278726, The Woodlands
Texas Oncology - Northeast Texas /ID# 278725, Tyler

招募中2/3 期

18 歲及以上 · 所有性別 · 更新於 2026年9月22日 · NCT07095452

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

The University of Texas MD Anderson Cancer Center, Houston

招募中2 期

12 歲及以上 · 所有性別 · 更新於 2026年9月22日 · NCT02693535

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

The University of Texas MD Anderson Cancer Center, Houston

招募中3 期

18 歲及以上 · 所有性別 · 更新於 2026年9月21日 · NCT07648264

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

MD Anderson Cancer Center, Houston

招募中2 期

所有年齡 · 所有性別 · 更新於 2026年9月18日 · NCT07382739

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

MD Anderson Cancer Center, Houston

招募中1/2 期

18 歲及以上 · 所有性別 · 更新於 2026年9月17日 · NCT04879043

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

University of Texas MD Anderson Cancer Center, Houston

招募中3 期

18 歲及以上 · 所有性別 · 更新於 2026年9月15日 · NCT06615479

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

UT Southwestern Medical Center, Dallas
University of Texas MD Anderson Cancer Center, Houston
Methodist HealthCare System of San Antonio Clinical Trials Office, Texas Transplant Institute, San Antonio

招募中2 期

18 歲及以上 · 所有性別 · 更新於 2026年9月14日 · NCT06297226

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

University of Texas - Southwestern Medical Center /ID# 271914, Dallas

招募中1/2 期

18 歲及以上 · 所有性別 · 更新於 2026年9月14日 · NCT06953960

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

University of Texas MD Anderson Cancer Center, Houston

招募中1/2 期

18 歲及以上 · 所有性別 · 更新於 2026年9月2日 · NCT06988488

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

Research Site, Houston

招募中1/2 期

18 歲及以上 · 所有性別 · 更新於 2026年8月27日 · NCT07681596

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Baylor University Medical Center, Investigational Drug Services, Department of Pharmacy, Dallas
Baylor University Medical Center, Dallas
Houston Methodist Cancer Center Infusion, Houston
還有 9 項

招募中3 期

18 歲及以上 · 所有性別 · 更新於 2026年8月24日 · NCT06152575